JP2020533273A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533273A5 JP2020533273A5 JP2020503686A JP2020503686A JP2020533273A5 JP 2020533273 A5 JP2020533273 A5 JP 2020533273A5 JP 2020503686 A JP2020503686 A JP 2020503686A JP 2020503686 A JP2020503686 A JP 2020503686A JP 2020533273 A5 JP2020533273 A5 JP 2020533273A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- tmmp
- amino acid
- mutant
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555499P | 2017-09-07 | 2017-09-07 | |
| US62/555,499 | 2017-09-07 | ||
| PCT/US2018/049756 WO2019051091A1 (en) | 2017-09-07 | 2018-09-06 | T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533273A JP2020533273A (ja) | 2020-11-19 |
| JP2020533273A5 true JP2020533273A5 (enExample) | 2021-10-28 |
Family
ID=65634643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503686A Pending JP2020533273A (ja) | 2017-09-07 | 2018-09-06 | 多量体ｔ細胞調節ポリペプチドおよびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20200148744A1 (enExample) |
| EP (1) | EP3678691A4 (enExample) |
| JP (1) | JP2020533273A (enExample) |
| KR (1) | KR20200040860A (enExample) |
| CN (1) | CN111050793A (enExample) |
| AU (1) | AU2018328280B2 (enExample) |
| BR (1) | BR112020004535A2 (enExample) |
| CA (1) | CA3070484A1 (enExample) |
| EA (1) | EA202090471A1 (enExample) |
| IL (2) | IL297361B2 (enExample) |
| MX (1) | MX2020002596A (enExample) |
| TW (1) | TWI918592B (enExample) |
| WO (1) | WO2019051091A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201808552XA (en) * | 2016-05-18 | 2018-10-30 | Cue Biopharma Inc | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| KR20240005989A (ko) | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| WO2019051127A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| TWI856047B (zh) * | 2018-12-19 | 2024-09-21 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| EP3719033A1 (en) | 2019-04-02 | 2020-10-07 | imusyn GmbH & Co. KG | Stabilized mhc i |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| JP2022536581A (ja) * | 2019-06-19 | 2022-08-18 | キュー バイオファーマ， インコーポレイテッド | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
| TW202128961A (zh) | 2019-11-20 | 2021-08-01 | 美商安維塔生物科學股份有限公司 | 細胞激素融合蛋白及其醫藥組合物及治療應用 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| TWI855242B (zh) * | 2020-03-18 | 2024-09-11 | 南韓商Ｇｉ醫諾微新股份有限公司 | 包含含有il-2蛋白與cd80蛋白之融合蛋白及抗癌藥物的用於治療癌症的藥學組成物 |
| EP4143329A4 (en) | 2020-04-28 | 2024-10-16 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| CN111592580A (zh) * | 2020-05-08 | 2020-08-28 | 中国药科大学 | 一种具有免疫检查点ctla-4抑制活性的多肽及其应用 |
| IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| WO2021230638A1 (en) * | 2020-05-12 | 2021-11-18 | Lg Chem, Ltd. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2022015880A2 (en) * | 2020-07-14 | 2022-01-20 | Cue Biopharma, Inc. | T-cell modulatory polypeptides with conjugation sites and methods of use thereof |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| CN113424794B (zh) * | 2021-04-16 | 2022-07-26 | 安徽农业大学 | 一种优质抗病型地方鸡新品系选育方法 |
| JP2025508958A (ja) * | 2022-03-01 | 2025-04-10 | クロスリンク セラピューティクス インク． | 抗癌剤としての免疫細胞機能のａｔｐ依存性アゴニスト |
| EP4709743A1 (en) * | 2023-05-11 | 2026-03-18 | Immudex ApS | Mhc class i molecules |
| WO2026125765A1 (en) | 2024-12-13 | 2026-06-18 | Immunoscape Pte. Ltd. | Combination therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030007978A1 (en) * | 1997-09-16 | 2003-01-09 | Burrows Gregory G. | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| EP1454138B1 (en) * | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| PL377028A1 (pl) * | 2002-03-26 | 2006-01-23 | Immunex Corporation | Sposoby wykorzystania ligandu Flt-3 w procedurach immunizacyjnych |
| AU2015209540B2 (en) * | 2014-01-21 | 2021-05-13 | Albert Einstein College Of Medicine, Inc. | Cellular platform for rapid and comprehensive T-cell immunomonitoring |
| JP6652932B2 (ja) * | 2014-06-18 | 2020-02-26 | アルバート アインシュタイン カレッジ オブ メディシン | ｓｙｎＴａｃポリペプチド及びその使用 |
| ES2774380T3 (es) * | 2014-08-29 | 2020-07-20 | Hoffmann La Roche | Politerapia de inmunocitocinas de variante de IL-2 dirigida a tumor y anticuerpos frente a PD-L1 humano |
-
2018
- 2018-09-06 MX MX2020002596A patent/MX2020002596A/es unknown
- 2018-09-06 AU AU2018328280A patent/AU2018328280B2/en not_active Ceased
- 2018-09-06 KR KR1020207008377A patent/KR20200040860A/ko not_active Ceased
- 2018-09-06 TW TW107131332A patent/TWI918592B/zh active
- 2018-09-06 BR BR112020004535-7A patent/BR112020004535A2/pt unknown
- 2018-09-06 JP JP2020503686A patent/JP2020533273A/ja active Pending
- 2018-09-06 IL IL297361A patent/IL297361B2/en unknown
- 2018-09-06 CN CN201880057027.0A patent/CN111050793A/zh active Pending
- 2018-09-06 EP EP18853880.5A patent/EP3678691A4/en active Pending
- 2018-09-06 WO PCT/US2018/049756 patent/WO2019051091A1/en not_active Ceased
- 2018-09-06 CA CA3070484A patent/CA3070484A1/en active Pending
- 2018-09-06 IL IL272085A patent/IL272085B2/en unknown
- 2018-09-06 EA EA202090471A patent/EA202090471A1/ru unknown
-
2020
- 2020-01-21 US US16/747,988 patent/US20200148744A1/en not_active Abandoned
-
2021
- 2021-08-24 US US17/410,453 patent/US20220119483A1/en not_active Abandoned
-
2023
- 2023-01-24 US US18/100,732 patent/US20240025964A1/en not_active Abandoned
-
2024
- 2024-05-02 US US18/653,683 patent/US20250002556A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Korman et al. | The foundations of immune checkpoint blockade and the ipilimumab approval decennial | |
| JP2022534846A5 (enExample) | ||
| Triebel | LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination | |
| Touloukian et al. | Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice | |
| JP2022515331A5 (enExample) | ||
| JP2021500855A5 (enExample) | ||
| Tutt et al. | T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody | |
| KR102436129B1 (ko) | T 세포 수용체 및 이의 용도 | |
| KR20220066075A (ko) | T-세포 조절 폴리펩타이드 및 이의 사용 방법 | |
| JP6722189B2 (ja) | 単量体Ｆｃドメイン | |
| JP2020514375A5 (enExample) | ||
| IL272085B (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| JP2022548472A5 (enExample) | ||
| US20160199479A1 (en) | T cell receptors | |
| CN115103852A (zh) | Prame tcr受体和其用途 | |
| JP2021500855A (ja) | 抗原提示ポリペプチドおよびその使用方法 | |
| JP2024512470A (ja) | Ｔ細胞調節ポリペプチド及びその使用方法 | |
| JP2018524326A5 (enExample) | ||
| Casares et al. | Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation | |
| CN110088126A (zh) | Icos配体变体免疫调节蛋白及其用途 | |
| JP2022515331A (ja) | 多量体ｔ細胞調節ポリペプチド及びその使用方法 | |
| CA3149583A1 (en) | Chimeric proteins in autoimmunity | |
| O’Herrin et al. | Antigen-specific blockade of T cells in vivo using dimeric MHC peptide | |
| US20240368246A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| JP2022536581A5 (enExample) |